Celldex Therapeutics Inc Net Assets
Celldex Therapeutics Inc net assets. Based on the latest financial reports, Celldex Therapeutics Inc (CLDX) has net assets worth $456.23 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($511.25 Million) and total liabilities ($55.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See how leveraged is Celldex Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $456.23 Million |
| % of Total Assets | 89.24% |
| Annual Growth Rate | N/A |
| 5-Year Change | 25.67% |
| 10-Year Change | 98.61% |
| Growth Volatility | 182.64 |
Net Assets of Celldex Therapeutics Inc (1985–2025)
Net assets of Celldex Therapeutics Inc from 1985 to 2025. This chart illustrates how Celldex Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore CLDX net asset momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Celldex Therapeutics Inc (1985–2025)
The table below shows the annual net assets of Celldex Therapeutics Inc from 1985 to 2025. For live market cap and overall valuation, see CLDX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $527.16 Million | -29.43% |
| 2024-12-31 | $747.00 Million | +74.06% |
| 2023-12-31 | $429.17 Million | +31.57% |
| 2022-12-31 | $326.20 Million | -22.24% |
| 2021-12-31 | $419.48 Million | +100.36% |
| 2020-12-31 | $209.36 Million | +122.66% |
| 2019-12-31 | $94.03 Million | -24.21% |
| 2018-12-31 | $124.06 Million | -47.51% |
| 2017-12-31 | $236.37 Million | -10.95% |
| 2016-12-31 | $265.43 Million | -8.51% |
| 2015-12-31 | $290.11 Million | +37.06% |
| 2014-12-31 | $211.66 Million | -33.81% |
| 2013-12-31 | $319.80 Million | +233.91% |
| 2012-12-31 | $95.77 Million | +39.36% |
| 2011-12-31 | $68.72 Million | -8.68% |
| 2010-12-31 | $75.25 Million | +2.02% |
| 2009-12-31 | $73.77 Million | +306.80% |
| 2008-12-31 | $18.13 Million | +195.22% |
| 2007-12-31 | $-19.04 Million | -981.25% |
| 2006-12-31 | $2.16 Million | -89.65% |
| 2005-12-31 | $20.89 Million | -45.61% |
| 2004-12-31 | $38.41 Million | +37.56% |
| 2003-12-31 | $27.92 Million | -10.93% |
| 2002-12-31 | $31.34 Million | -30.76% |
| 2001-12-31 | $45.27 Million | -16.06% |
| 2000-12-31 | $53.93 Million | +209.72% |
| 1999-12-31 | $17.41 Million | -7.38% |
| 1998-12-31 | $18.80 Million | +198.41% |
| 1997-12-31 | $6.30 Million | -59.62% |
| 1996-12-31 | $15.60 Million | -2.50% |
| 1995-12-31 | $16.00 Million | -9.09% |
| 1994-12-31 | $17.60 Million | -39.52% |
| 1993-12-31 | $29.10 Million | +45.50% |
| 1992-12-31 | $20.00 Million | +92.31% |
| 1991-12-31 | $10.40 Million | 0.00% |
| 1990-12-31 | $10.40 Million | -20.61% |
| 1989-12-31 | $13.10 Million | +55.95% |
| 1988-12-31 | $8.40 Million | -9.68% |
| 1987-12-31 | $9.30 Million | -10.58% |
| 1986-12-31 | $10.40 Million | +516.00% |
| 1985-12-31 | $-2.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Celldex Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 181108100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Celldex Therapeutics Inc Net Assets Breakdown (December 2025)
Celldex Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $67.00K | 0.01% |
| Other Comprehensive Income | $3.63 Million | 0.69% |
| Other Components | $2.34 Billion | 443.40% |
| Total Equity | $527.16 Million | 100.00% |
Celldex Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Celldex Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northeast Securities Co Ltd
SHE:000686
|
$2.36 Billion |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
$2.36 Billion |
|
ADEIA CORP
NASDAQ:ADEA
|
$2.36 Billion |
|
Tofas Turk Otomobil Fabrikasi AS
IS:TOASO
|
$2.37 Billion |
|
Hyundai Mar&Fi
KO:001450
|
$2.36 Billion |
|
Euronet Worldwide Inc
NASDAQ:EEFT
|
$2.36 Billion |
|
ShenZhen Special Economic Zone Real Estate & Properties Group Co Ltd
SHE:000029
|
$2.36 Billion |
|
Boyd Group Services Inc.
TO:BYD
|
$2.36 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celldex Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 747,005,000 to 527,165,000, a change of -219,840,000 (-29.4%).
- Net loss of 258,800,000 reduced equity.
- Other comprehensive income increased equity by 312,000.
- Other factors increased equity by 38,648,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-258.80 Million | -49.09% |
| Other Comprehensive Income | $312.00K | +0.06% |
| Other Changes | $38.65 Million | +7.33% |
| Total Change | $- | -29.43% |
Book Value vs Market Value Analysis
This analysis compares Celldex Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $-54.72 | $30.10 | x |
| 1986-12-31 | $227.32 | $30.10 | x |
| 1987-12-31 | $203.18 | $30.10 | x |
| 1988-12-31 | $181.75 | $30.10 | x |
| 1989-12-31 | $247.48 | $30.10 | x |
| 1990-12-31 | $177.26 | $30.10 | x |
| 1991-12-31 | $177.26 | $30.10 | x |
| 1992-12-31 | $264.11 | $30.10 | x |
| 1993-12-31 | $307.70 | $30.10 | x |
| 1994-12-31 | $185.94 | $30.10 | x |
| 1995-12-31 | $164.74 | $30.10 | x |
| 1996-12-31 | $129.44 | $30.10 | x |
| 1997-12-31 | $42.83 | $30.10 | x |
| 1998-12-31 | $102.00 | $30.10 | x |
| 1999-12-31 | $71.11 | $30.10 | x |
| 2000-12-31 | $185.13 | $30.10 | x |
| 2001-12-31 | $140.53 | $30.10 | x |
| 2002-12-31 | $93.32 | $30.10 | x |
| 2003-12-31 | $80.39 | $30.10 | x |
| 2004-12-31 | $94.75 | $30.10 | x |
| 2005-12-31 | $50.71 | $30.10 | x |
| 2006-12-31 | $5.24 | $30.10 | x |
| 2007-12-31 | $-35.02 | $30.10 | x |
| 2008-12-31 | $19.13 | $30.10 | x |
| 2009-12-31 | $55.82 | $30.10 | x |
| 2010-12-31 | $35.42 | $30.10 | x |
| 2011-12-31 | $26.10 | $30.10 | x |
| 2012-12-31 | $24.89 | $30.10 | x |
| 2013-12-31 | $60.13 | $30.10 | x |
| 2014-12-31 | $35.51 | $30.10 | x |
| 2015-12-31 | $44.84 | $30.10 | x |
| 2016-12-31 | $39.21 | $30.10 | x |
| 2017-12-31 | $27.58 | $30.10 | x |
| 2018-12-31 | $11.88 | $30.10 | x |
| 2019-12-31 | $6.48 | $30.10 | x |
| 2020-12-31 | $7.06 | $30.10 | x |
| 2021-12-31 | $9.78 | $30.10 | x |
| 2022-12-31 | $6.96 | $30.10 | x |
| 2023-12-31 | $8.86 | $30.10 | x |
| 2024-12-31 | $11.60 | $30.10 | x |
| 2025-12-31 | $7.93 | $30.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celldex Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17253.33%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-49.09%) is above the historical average (-77.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 0.00% | -1700.00% | 0.03x | 0.00x | $-1.45 Million |
| 1986 | -11.54% | -54.55% | 0.15x | 1.40x | $-2.24 Million |
| 1987 | -11.83% | -23.91% | 0.35x | 1.40x | $-2.03 Million |
| 1988 | -11.90% | -9.17% | 0.83x | 1.57x | $-1.84 Million |
| 1989 | -25.95% | -33.33% | 0.65x | 1.19x | $-4.71 Million |
| 1990 | -32.69% | -33.33% | 0.77x | 1.27x | $-4.44 Million |
| 1991 | -44.23% | -51.69% | 0.67x | 1.27x | $-5.64 Million |
| 1992 | -18.27% | -54.55% | 0.29x | 1.14x | $-5.57 Million |
| 1993 | -26.80% | -86.67% | 0.27x | 1.14x | $-10.71 Million |
| 1994 | -65.91% | -165.71% | 0.34x | 1.18x | $-13.36 Million |
| 1995 | -51.88% | -207.50% | 0.22x | 1.16x | $-9.90 Million |
| 1996 | -69.23% | -981.82% | 0.06x | 1.10x | $-12.36 Million |
| 1997 | -207.94% | -1091.67% | 0.12x | 1.56x | $-13.73 Million |
| 1998 | -275.53% | -2354.55% | 0.10x | 1.21x | $-53.68 Million |
| 1999 | -64.95% | -762.33% | 0.07x | 1.14x | $-13.05 Million |
| 2000 | -40.75% | -2879.32% | 0.01x | 1.18x | $-27.37 Million |
| 2001 | -50.26% | -680.03% | 0.06x | 1.18x | $-27.28 Million |
| 2002 | -44.12% | -206.26% | 0.19x | 1.12x | $-16.96 Million |
| 2003 | -45.38% | -273.47% | 0.15x | 1.12x | $-15.46 Million |
| 2004 | -34.38% | -192.51% | 0.15x | 1.19x | $-17.04 Million |
| 2005 | -86.63% | -585.96% | 0.08x | 1.75x | $-20.19 Million |
| 2006 | -942.81% | -413.17% | 0.08x | 28.45x | $-20.59 Million |
| 2007 | 0.00% | -424.05% | 0.14x | 0.00x | $-19.73 Million |
| 2008 | -261.95% | -637.12% | 0.11x | 3.85x | $-49.31 Million |
| 2009 | -49.51% | -240.61% | 0.11x | 1.90x | $-43.90 Million |
| 2010 | -3.37% | -5.41% | 0.43x | 1.46x | $-10.06 Million |
| 2011 | -65.19% | -483.53% | 0.09x | 1.43x | $-51.67 Million |
| 2012 | -61.73% | -527.79% | 0.09x | 1.31x | $-68.70 Million |
| 2013 | -25.50% | -1983.70% | 0.01x | 1.09x | $-113.53 Million |
| 2014 | -55.79% | -3292.81% | 0.01x | 1.17x | $-139.25 Million |
| 2015 | -43.85% | -2321.11% | 0.02x | 1.16x | $-156.21 Million |
| 2016 | -48.42% | -1894.05% | 0.02x | 1.44x | $-155.07 Million |
| 2017 | -39.36% | -730.06% | 0.04x | 1.34x | $-116.67 Million |
| 2018 | -121.86% | -1585.07% | 0.06x | 1.26x | $-163.59 Million |
| 2019 | -54.11% | -1423.96% | 0.03x | 1.31x | $-60.28 Million |
| 2020 | -28.55% | -805.88% | 0.03x | 1.13x | $-80.72 Million |
| 2021 | -16.81% | -1516.04% | 0.01x | 1.06x | $-112.46 Million |
| 2022 | -34.43% | -4765.59% | 0.01x | 1.08x | $-144.95 Million |
| 2023 | -32.95% | -2054.76% | 0.01x | 1.08x | $-184.35 Million |
| 2024 | -21.13% | -2248.76% | 0.01x | 1.06x | $-232.56 Million |
| 2025 | -49.09% | -17253.33% | 0.00x | 1.11x | $-311.52 Million |
Industry Comparison
This section compares Celldex Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celldex Therapeutics Inc (CLDX) | $456.23 Million | 0.00% | 0.12x | $2.36 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more